Anastrozole
Arimidex (anastrozole) is a small molecule pharmaceutical. Anastrozole was first approved as Arimidex on 1995-12-27. It is used to treat breast neoplasms in the USA. The pharmaceutical is active against aromatase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Arimidex (generic drugs available since 2010-06-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Anastrozole
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ARIMIDEX | ANI PHARMS | N-020541 RX | 1995-12-27 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
anastrozole | ANDA | 2023-05-01 |
arimidex | New Drug Application | 2019-10-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
S0170 | Anastrozole, oral, 1 mg |
Clinical
Clinical Trials
277 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 16 | 93 | 57 | 10 | 28 | 198 |
Male breast neoplasms | D018567 | — | 5 | 2 | 1 | 2 | 10 | ||
Hypogonadism | D007006 | E23.0 | 1 | 3 | — | 2 | 1 | 7 | |
Invasive hydatidiform mole | D002820 | D39.2 | 2 | 1 | 2 | 1 | — | 6 | |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | 2 | 3 | 6 |
Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 1 | — | 2 | — | 4 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Triple negative breast neoplasms | D064726 | — | 8 | 4 | — | — | 12 | ||
Neoplasms | D009369 | C80 | 5 | 3 | 1 | — | — | 8 | |
Ductal carcinoma breast | D018270 | — | — | 2 | — | — | 2 | ||
Gynecomastia | D006177 | HP_0000771 | N62 | — | 1 | 1 | — | — | 2 |
Progression-free survival | D000077982 | — | — | 1 | — | — | 1 | ||
Bone density | D015519 | EFO_0003923 | M85 | — | — | 1 | — | — | 1 |
Oligospermia | D009845 | N46.1 | — | — | 1 | — | — | 1 | |
Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | 1 | 1 | — | — | 1 |
Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 8 | 1 | — | — | 1 | 10 | ||
Endometrial neoplasms | D016889 | EFO_0004230 | 2 | 4 | — | — | — | 5 | |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | — | — | — | 4 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | 1 | — | — | 1 | 3 |
Non-small-cell lung carcinoma | D002289 | 1 | 1 | — | — | — | 2 | ||
Pulmonary arterial hypertension | D000081029 | — | 2 | — | — | — | 2 | ||
Intraductal carcinoma noninfiltrating | D002285 | D05.1 | — | 2 | — | — | — | 2 | |
Eunuchism | D005058 | EFO_0007266 | E29.1 | — | 1 | — | — | — | 1 |
Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
Peritoneal neoplasms | D010534 | — | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | 1 | 2 |
Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | 1 | — | — | — | — | 1 |
Breast density | D000071060 | 1 | — | — | — | — | 1 | ||
Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | — | — | 5 | 5 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | — | — | 1 | 1 |
Silver-russell syndrome | D056730 | Orphanet_813 | Q87.19 | — | — | — | — | 1 | 1 |
Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | 1 | 1 | |
Musculoskeletal pain | D059352 | — | — | — | — | 1 | 1 | ||
Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ANASTROZOLE |
INN | anastrozole |
Description | Anastrozole is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile. |
Classification | Small molecule |
Drug class | aromatase inhibitors (imidazole/triazole derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1 |
Identifiers
PDB | — |
CAS-ID | 120511-73-1 |
RxCUI | 84857 |
ChEMBL ID | CHEMBL1399 |
ChEBI ID | 2704 |
PubChem CID | 2187 |
DrugBank | DB01217 |
UNII ID | 2Z07MYW1AZ (ChemIDplus, GSRS) |
Target
Agency Approved
CYP19A1
CYP19A1
Organism
Homo sapiens
Gene name
CYP19A1
Gene synonyms
ARO1, CYAR, CYP19
NCBI Gene ID
Protein name
aromatase
Protein synonyms
CYPXIX, Cytochrome P-450AROM, Cytochrome P450 19A1, cytochrome P450, family 19, subfamily A, polypeptide 1, cytochrome P450, subfamily XIX (aromatization of androgens), Estrogen synthase, estrogen synthetase, flavoprotein-linked monooxygenase, microsomal monooxygenase
Uniprot ID
Mouse ortholog
Cyp19a1 (13075)
aromatase (P28649)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Arimidex - AstraZeneca
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,811 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
10,274 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more